Analysts: more sales Pharming

Tomorrow the Dutch company Pharming will publish its past quarters results. For this year the company, based in Leiden revenue will be around 290.36 million euros. This is according to the average of the analysts' estimates. The expected revenue would be the highest in her history. This is hugely more than 2023's revenue of 245.32 million euros.

Historical revenues and results Pharming plus estimates 2023

Pharming office Lead © Pharming

The analysts expect for 2024 a net loss of 11 million euros. For this year the consensus of the result per share is a loss of 2 cent. Based on this the price/earnings-ratio is -42.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a good 3.55 percent.

Most recent target prices around 2 euros

The most recent recommendations for the biotech company are from RBC Capital Markets, RBC Capital Markets and RBC Capital Markets.

Pharming 's market value equals around 553.63 million .

Historical stock prices Pharming

On Tuesday the stock closed at 0.84 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.